Trevena ( (TRVN) ) has issued an announcement.
Trevena, Inc. is undergoing significant changes amidst financial challenges, including director resignations and cost-cutting measures, while continuing to explore strategic alternatives for its assets. Despite a reverse stock split, the company faced delisting from Nasdaq, moving its stock to OTC Pink Sheets. The company reported a reduced third-quarter loss and maintains its focus on CNS disorder treatments, with OLINVYK and investigational drugs like TRV045 being central to its pipeline.
For detailed information about TRVN stock, go to TipRanks’ Stock Analysis page.
